查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401859

2030 年药物基因组学市场预测：按配销通路、技术、应用、最终用户和地区分類的全球分析

Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球药物基因组学市场规模为 166.6 亿美元，预计预测期内复合年增长率为 11.1%，到 2030 年将达到 348.1 亿美元。

透过分析影响个体对特定药物反应的人类遗传变异来开发药物的研究称为药物基因组学。这种方法对于精准医学至关重要，可以根据遗传标记提供个人化治疗计画。改善患者治疗效果、减少副作用、提高药物疗效并提供更具成本效益的医疗保健至关重要。

根据美国癌症研究所2020年9月发布的资料，预计2020年美国将有1,806,590人新诊断出癌症，606,520人将死于癌症。

个人化医疗的普及

个人化医疗是一种根据个人的遗传、基因组和临床特征量身订做医疗照护的方法。透过客製化医疗介入措施，我们的目标是最大限度地提高治疗效果、最大限度地减少副作用并改善患者的治疗结果。随着患者和医疗保健提供者越来越意识到药物基因组学的潜在益处，对基因检测和个体化治疗计划的需求正在增加。此外，製药公司也投资基于基因组资料的标靶治疗。患者需求、临床相关性和产业创新的融合正在推动药物基因组学市场的成长。

成本壁垒

成本障碍是药物基因体学市场的主要抑制因素。基因检测和药物基因组学服务价格昂贵，使得许多患者和医疗系统无法获得这些服务。 核酸定序、资料分析和解释的高成本可能会限制药物基因组学的采用，特别是在资源有限的环境中。这些经济负担导致无法平等地获得个人化医疗的好处，并加剧了医疗保健差距。

基因检测技术的进展

基因检测的进步可以透过降低成本、提高可及性和扩大检测的可用性来刺激成长。随着科技的进步，基因检测变得更加可用、更便宜且更准确。此外，用户友好的家庭检测套组和行动健康应用程式的开发使患者和医疗保健专业人员的测试过程变得更加容易。此外，这些发展不仅简化了个体遗传资讯的可用性，而且还促进将药物基因组资料纳入标准治疗方案。基因检测的广泛普及使得药物基因组学市场占有率的扩大和个人化医疗的广泛采用成为可能。

资料隐私和安全

遗传资讯高度敏感，处理不当或诈欺存取该资料可能会导致隐私侵犯、资讯盗窃和歧视。由于担心潜在的滥用，患者可能不愿意接受基因检测或共用资料。此外，保护遗传资讯的法律规范不断发展，可能为医疗保健提供者和製药公司带来合规挑战。因此，导致市场成长下降。

COVID-19 的影响

COVID-19 的爆发对市场产生了多方面的影响。一方面，它加速了数位医疗的普及，包括远端医疗和远端监控，可以透过促进资料共用和患者咨询来补充药物基因组学。大流行的紧迫性也导致医疗保健和製药领域的研究和投资增加，这可能会刺激药物基因组学的进步。然而，也有负面影响。许多医疗保健资源和研究工作都针对 COVID-19，这可能会减缓药物基因组学计划的进展。由于封锁和安全问题，药物基因组治疗的临床试验可能会被推迟或中断。

DNA定序部分预计将成为预测期内最大的部分

预计DNA定序部分将占最大占有率。 DNA定序涉及确定个体基因组中 DNA 碱基的确切顺序。透过分析遗传变异，研究人员和医疗保健提供者可以识别与药物反应和疾病感受性相关的特定基因和遗传标记。这些资讯允许治疗方法定制，并确保为患者提供最有效和最安全的治疗方法选择。此外，次世代定序等DNA测序技术的进步使得基因组资料的获取速度更快、更具成本效益，推动了这一领域的成长，并增加了药物基因组学在医疗保健领域的潜在应用。

医院和诊所领域预计在预测期内复合年增长率最高。

预计医院和诊所部门在预测期内将出现良好的成长。医疗机构利用药物基因组学测试来定製药物治疗计划，并确保药物对个别患者有效且安全。药物基因组学帮助临床医生确定最合适的药物治疗和给药，最大限度地减少副作用并优化患者的治疗结果。此外，它还可以帮助选择从癌症到心血管疾病等多种疾病的治疗方法。随着个人化医疗需求的增加，医院和诊所必须将药物基因组学纳入日常临床实践，透过提供个体化、资料主导的治疗计划来彻底改变医疗保健。

占有率最大的地区

在估计期间，亚太地区占据最大的市场占有率。亚太地区是药物基因体学的重要且快速成长的市场。该地区面临着癌症、心血管疾病和糖尿病等慢性疾病日益沉重的负担，推动了对个人化医疗和药物基因组学解决方案的需求。中国、日本和韩国等亚太地区国家正在大力投资基因组学研究，在了解影响药物反应和疾病的遗传因素方面取得了重大进展。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。北美拥有先进的医疗保健系统，包括成熟的医院、研究机构和製药公司，为药物基因组学的发展提供了坚实的基础。美国FDA 等监管机构正在积极认识到药物基因组学在药物开发、核准和标籤中的重要性，这正在加速采用。此外，北美製药公司正在药物基因组学方面投入巨资，从而开发了许多个体化治疗方法。该地区处于药物基因组学研究的前沿，在基因组研究、临床试验和标靶治疗开发方面进行了大量投资。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球药物基因体学市场：按配销通路

  • 医院药房
  • 零售药房
  • 线上药房

第六章全球药物基因体学市场：依技术分类

  • DNA序列测定
  • 聚合酶炼式反应
  • 微阵列
  • 质谱
  • 电泳

第七章全球药物基因体学市场：依应用分类

  • 药物研发
  • 肿瘤学
  • 神经病学
  • 疼痛管理
  • 心血管疾病
  • 精神病学
  • 感染疾病
  • 其他用途

第八章全球药物基因组学市场：依最终用户分类

  • 医院和诊所
  • 研究和学术机构
  • 其他最终用户

第九章全球药物基因体学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Novartis AG
  • Ferndale Pharma Group, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Abbott
  • Bayer AG
  • Thermo Fisher Scientific, Inc.
  • Admera Health
  • Agilent Technologies
Product Code: SMRC24379

According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $16.66 billion in 2023 and is expected to reach $34.81 billion by 2030 growing at a CAGR of 11.1% during the forecast period. The study of developing drugs by analysing genetic variations in humans that affect an individual's response to a particular drug is known as pharmacogenomics. This approach is vital for precision medicine, offering personalised treatment plans based on genetic markers. It is essential to improving patient outcomes, reducing adverse drug reactions, enhancing medication efficacy, and providing more cost-effective healthcare.

According to data published by National Cancer Institute in September 2020, stated that an estimated 1,806,590 new cases of cancer will be diagnosed in the U.S. and 606,520 people will die from the disease in 2020.

Market Dynamics:

Driver:

Increasing adoption of personalized medicine

Personalised medicine is an approach that tailors medical treatments to an individual's genetic, genomic, and clinical characteristics. It aims to maximise treatment effectiveness, minimise side effects, and improve patient outcomes by customising healthcare interventions. As patients and healthcare providers become more aware of the potential benefits of pharmacogenomics, the demand for genetic testing and personalised treatment plans is on the rise. Furthermore, pharmaceutical companies are also investing in targeted therapies based on genomic data. This convergence of patient demand, clinical relevance, and industry innovation is propelling the growth of the pharmacogenomics market.

Restraint:

Cost barriers

Cost barriers pose a significant restraint on the Pharmacogenomics market. Genetic testing and pharmacogenomic services can be expensive, making them inaccessible to many patients and healthcare systems. The high costs of DNA sequencing, data analysis, and interpretation can limit the adoption of pharmacogenomics, especially in resource-constrained environments. This financial burden can result in unequal access to the benefits of personalised medicine, exacerbating healthcare disparities.

Opportunity:

Advancements in genetic testing technologies

Developments in genetic testing can spur growth by lowering the cost, increasing accessibility, and expanding the availability of testing. Genetic testing is getting easier to obtain, less expensive, and more accurate as technology advances. Furthermore, the process is made easier for patients and healthcare professionals by the creation of user-friendly at-home testing kits and mobile health applications. Moreover, these developments not only simplify genetic information availability for individuals but also make it easier to incorporate pharmacogenomic data into standard therapeutic procedures. Growing pharmacogenomics market share and wider adoption of personalised medicine are made possible by the increasing prevalence of genetic testing.

Threat:

Data privacy and security

Genetic information is highly sensitive, and the mishandling or unauthorised access to this data could lead to privacy breaches, identity theft, or discrimination. Patients may be hesitant to undergo genetic testing or share their data, fearing potential misuse. Furthermore, regulatory frameworks for safeguarding genetic information are continually evolving and can create compliance challenges for healthcare providers and pharmaceutical companies. Hence, it will lead to a decrease in market growth.

COVID-19 Impact

The COVID-19 pandemic has had a multifaceted impact on the market. On one hand, it accelerated the adoption of digital health, including telehealth and remote monitoring, which can complement pharmacogenomics by facilitating data sharing and patient consultations. The urgency of the pandemic also led to increased research and investment in healthcare and pharmaceuticals, potentially driving advancements in pharmacogenomics. However, there were negative effects as well. Many healthcare resources and research efforts were redirected toward COVID-19, potentially slowing the progress of pharmacogenomics projects. Clinical trials for pharmacogenomic therapies may have been delayed or disrupted due to lockdowns and safety concerns.

The DNA Sequencing segment is expected to be the largest during the forecast period

The DNA Sequencing segment is estimated to hold the largest share. DNA sequencing involves determining the precise order of DNA bases in an individual's genome. By analysing genetic variations, researchers and healthcare providers can identify specific genes and genetic markers relevant to drug response and disease susceptibility. This information enables the customization of medical treatments, ensuring the most effective and safe therapeutic options for patients. In addition, advances in DNA sequencing technologies, such as next-generation sequencing, have made it faster and more cost-effective to obtain genomic data, driving the growth of this segment and expanding the potential applications of pharmacogenomics in healthcare.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The healthcare facilities utilise pharmacogenomic testing to customise drug treatment plans, ensuring that medications are both effective and safe for individual patients. Pharmacogenomics can help clinicians identify the most suitable drug therapies and dosages, minimising adverse reactions and optimising patient outcomes. Furthermore, it aids in the selection of treatments for various medical conditions, from cancer to cardiovascular diseases. As the demand for personalised medicine grows, hospitals and clinics are essential in integrating pharmacogenomics into routine clinical practice, revolutionising healthcare by providing individualised, data-driven treatment plans.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a significant and rapidly growing market for pharmacogenomics. The region faces a rising burden of chronic diseases, including cancer, cardiovascular diseases, and diabetes, which has led to a growing demand for personalised medicine and pharmacogenomic solutions. Countries in the Asia-Pacific region, such as China, Japan, and South Korea, have made substantial investments in genomics research, leading to significant advancements in understanding genetic factors influencing drug responses and diseases.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America boasts advanced healthcare systems, including well-established hospitals, research institutions, and pharmaceutical companies, providing a solid foundation for the growth of pharmacogenomics. Regulatory agencies, such as the FDA in the United States, have been proactive in recognising the importance of pharmacogenomics in drug development, approval, and labelling, which accelerates its adoption. Furthermore, North American pharmaceutical companies have heavily invested in pharmacogenomics, resulting in the development of numerous personalised therapies. The region is at the forefront of pharmacogenomic research, with substantial investments in genomic studies, clinical trials, and the development of targeted therapies.

Key players in the market:

Some of the key players in the Pharmacogenomics Market include Novartis AG, Ferndale Pharma Group, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Lupin, NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boehringer Ingelheim International GmbH, Abbott, Bayer AG, Thermo Fisher Scientific, Inc., Admera Health and Agilent Technologies.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Technologies Covered:

  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Mass Spectrometry
  • Electrophoresis

Applications Covered:

  • Drug Discovery
  • Oncology
  • Neurology
  • Pain Management
  • Cardiovascular diseases
  • Psychiatry
  • Infectious diseases
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Research Institutions and Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Market, By Distribution Channel

  • 5.1 Introduction
  • 5.2 Hospital Pharmacy
  • 5.3 Retail Pharmacy
  • 5.4 Online Pharmacy

6 Global Pharmacogenomics Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Sequencing
  • 6.3 Polymerase Chain Reaction
  • 6.4 Microarray
  • 6.5 Mass Spectrometry
  • 6.6 Electrophoresis

7 Global Pharmacogenomics Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Discovery
  • 7.3 Oncology
  • 7.4 Neurology
  • 7.5 Pain Management
  • 7.6 Cardiovascular diseases
  • 7.7 Psychiatry
  • 7.8 Infectious diseases
  • 7.9 Other Applications

8 Global Pharmacogenomics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Research Institutions and Academic Institutes
  • 8.4 Other End Users

9 Global Pharmacogenomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Ferndale Pharma Group, Inc.
  • 11.3 Mylan N.V.
  • 11.4 F. Hoffmann-La Roche Ltd
  • 11.5 Takeda Pharmaceutical Company Limited
  • 11.6 Pfizer Inc.
  • 11.7 AstraZeneca
  • 11.8 Merck & Co., Inc.
  • 11.9 Eli Lilly and Company
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Lupin
  • 11.12 NATCO Pharma Limited
  • 11.13 Teva Pharmaceutical Industries Ltd
  • 11.14 AbbVie Inc.
  • 11.15 Boehringer Ingelheim International GmbH
  • 11.16 Abbott
  • 11.17 Bayer AG
  • 11.18 Thermo Fisher Scientific, Inc.
  • 11.19 Admera Health
  • 11.20 Agilent Technologies

List of Tables

  • Table 1 Global Pharmacogenomics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 3 Global Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 4 Global Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 5 Global Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 6 Global Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 7 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 8 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 9 Global Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 10 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 11 Global Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 12 Global Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 14 Global Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 15 Global Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 16 Global Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 17 Global Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 18 Global Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 19 Global Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 20 Global Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 21 Global Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 23 Global Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 24 Global Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 27 North America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 28 North America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 North America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 30 North America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 32 North America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 33 North America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 34 North America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 35 North America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 36 North America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 38 North America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 39 North America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 40 North America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 41 North America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 42 North America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 43 North America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 44 North America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 45 North America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 46 North America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 47 North America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 48 North America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 51 Europe Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 52 Europe Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 53 Europe Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 54 Europe Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 55 Europe Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 56 Europe Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 57 Europe Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 58 Europe Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 59 Europe Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 60 Europe Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 62 Europe Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 63 Europe Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 64 Europe Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 65 Europe Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 66 Europe Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 67 Europe Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 68 Europe Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 69 Europe Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 70 Europe Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 71 Europe Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 72 Europe Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 75 Asia Pacific Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 76 Asia Pacific Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 77 Asia Pacific Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 78 Asia Pacific Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 79 Asia Pacific Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 80 Asia Pacific Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 81 Asia Pacific Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 82 Asia Pacific Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 83 Asia Pacific Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 84 Asia Pacific Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 85 Asia Pacific Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 86 Asia Pacific Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 87 Asia Pacific Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 88 Asia Pacific Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 89 Asia Pacific Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 90 Asia Pacific Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 91 Asia Pacific Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 92 Asia Pacific Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 93 Asia Pacific Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 Asia Pacific Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 95 Asia Pacific Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 96 Asia Pacific Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 99 South America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 100 South America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 101 South America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 102 South America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 103 South America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 104 South America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 105 South America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 106 South America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 107 South America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 108 South America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 109 South America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 110 South America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 111 South America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 112 South America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 113 South America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 114 South America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 115 South America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 116 South America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 117 South America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 118 South America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 119 South America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 120 South America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 123 Middle East & Africa Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 126 Middle East & Africa Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 127 Middle East & Africa Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 128 Middle East & Africa Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 129 Middle East & Africa Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 130 Middle East & Africa Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 131 Middle East & Africa Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 132 Middle East & Africa Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 133 Middle East & Africa Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 134 Middle East & Africa Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 135 Middle East & Africa Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 136 Middle East & Africa Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 137 Middle East & Africa Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 138 Middle East & Africa Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 139 Middle East & Africa Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 140 Middle East & Africa Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 141 Middle East & Africa Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 142 Middle East & Africa Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 143 Middle East & Africa Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 144 Middle East & Africa Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)